SEC For	m 4 FORM	4 U	NITEI	D STAT	ES S	SEC	URITIE	S AN	DE	XCHAN	IGE C	OM	MISSIC	)N					
		•	Washington, D.C. 20549												OMB APPROVAL				
to Sec obligat	this box if no lo tion 16. Form 4 ions may contin tion 1(b).	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHI Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										RSHIP	Estin	OMB Number:         3235-0287           Estimated average burden            hours per response:         0.5					
1. Name and Address of Reporting Person <sup>*</sup> Cheng Andrew					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Akero Therapeutics, Inc.</u> [ AKRO ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				wner		
(Last) C/O AK	(Last) (First) (Middle) C/O AKERO THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 03/13/2024								X Officer (give title Other (specify below) below) President and CEO					
601 GATEWAY BOULEVARD, SUITE 350					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SOUTH SAN FRANCISCO CA 94080														m filed by Mo	led by One Reporting Person led by More than One Reporting				
(City)	(St	ate) (.	Zip)			Rule 10b5-1(c) Transaction Indication            Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	l - No	n-Deriva	tive S	Secur	rities Acq	uired	, Dis	posed of	, or Be	nefici	ally Ow	ned					
Date				Date	Transaction ate Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		ction Instr.	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			nd Secu Bene Owne	ficially d Following	Form (D) o	n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price		action(s) 3 and 4)			(Instr. 4)		
Common Stock 03/13/2					2024			<b>S</b> <sup>(1)</sup>		1,969	D	\$28.	33 5	89,447		D			
		Та					ies Acqu varrants,							əd					
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Exect ecurity or Exercise (Month/Day/Year) if any		if any	emed 4. ion Date, Transa Code (I /Day/Year) 8)			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price o Derivative Security (Instr. 5)		e S Ily I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirec Beneficial Ownershi (Instr. 4)		

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.

Date Exercisable Expiration Date

## /s/ Jonathan Young, Attorney-03/15/2024

Amount or Number

of Shares

in-Fact

Title

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

v

Code

(A) (D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.